Financial analyst price targets and predictive models for Outlook Therapeutics (OTLK) heading into 2027 project wide target ranges reflecting commercial execution uncertainties, with median Wall Street targets hovering around $4.00 per share and speculative high algorithmic estimates reaching significantly higher, contingent upon successful U.S. product launches and sales revenue scaling.